Waystone has launched the Invenomic US Equity Long/Short UCITS Fund on the MontLake UCITS Platform ICAV. The fund launched with USD35 million in AUM with a strong pipeline to grow quickly to USD100 million.
The fund joins the Waystone Investment Solutions product suite at Waystone Fund Management.
The Invenomic US Equity Long/Short UCITS Fund, managed by Invenomic Capital Management LP, is a fundamentally driven diversified all cap US equity long/short strategy with a strong value bias.
Invenomic Capital Management LP was founded in 2015 by Ali Motamed. For over 17 years, Motamed has developed and managed what has become the Invenomic strategy. The objective of the fund is to achieve long-term capital appreciation. To achieve this, the Invenomic strategy adopts three core principles: 1) investing in fundamentally sound companies 2) disciplined short selling and 3) diversification – an essential risk management tool.
Motamed says: “We are very pleased to bring our strategy to the European market with the help of Waystone. We have been running our strategy with daily liquidity in the US for over four years now and feel that a UCITS fund available to non-US investors is a crucial next step in the development of our business. With this launch we can offer our long/short equity strategy to investors all over the world.”
Kenneth Sim, Global Head of Distribution, Waystone, says: “We are excited to be partnering with Invenomic on the launch of its UCITS Fund. Following a decade of clear outperformance of growth over value, we have seen a clear shift in demand from investors looking for value-tilted strategies that can generate absolute returns through alpha. In response to this, the Waystone Investment Solutions team has sourced and partnered with Invenomic Capital Management LP to bring its strong track record and expertise to the European UCITS market, which has come at a time where such value-related strategies are starting to experience their long overdue tailwinds. We feel that the strategy is a compelling investment opportunity for our clients looking to diversify their portfolios. We look forward to building a successful partnership with Invenomic.”
